NAVIGATE ESUS: Multicenter, Randomized, Double-Blind, Phase III Trial of Rivaroxaban vs. Aspirin for the Prevention of Recurrent Stroke and Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source
机构：[1]Sanno Hosp, Sanno Med Ctr, Tokyo, Japan;[2]Seoul Natl Univ Hosp, Seoul 110744, South Korea;[3]Beijing Tiantan Hosp, Beijing, Peoples R China;首都医科大学附属天坛医院[4]Univ Western Australia, Perth, WA 6009, Australia;[5]McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada;[6]Bayer Healthcare, Leverkusen, Germany;[7]Bayer Healthcare, Wuppertal, Germany;[8]Bayer Healthcare, Whippany, NJ USA
第一作者机构：[1]Sanno Hosp, Sanno Med Ctr, Tokyo, Japan;
推荐引用方式(GB/T 7714)：
Uchiyama S.,Yoon B. W.,Wang Y.,et al.NAVIGATE ESUS: Multicenter, Randomized, Double-Blind, Phase III Trial of Rivaroxaban vs. Aspirin for the Prevention of Recurrent Stroke and Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source[J].CEREBROVASCULAR DISEASES.2015,40:34-35.
APA：
Uchiyama, S.,Yoon, B. W.,Wang, Y.,Hankey, G. J.,Shoamanesh, A....&Hart, R. G..(2015).NAVIGATE ESUS: Multicenter, Randomized, Double-Blind, Phase III Trial of Rivaroxaban vs. Aspirin for the Prevention of Recurrent Stroke and Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source.CEREBROVASCULAR DISEASES,40,
MLA：
Uchiyama, S.,et al."NAVIGATE ESUS: Multicenter, Randomized, Double-Blind, Phase III Trial of Rivaroxaban vs. Aspirin for the Prevention of Recurrent Stroke and Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source".CEREBROVASCULAR DISEASES 40.(2015):34-35
